



## Clinical trial results:

**A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)**

### Summary

EudraCT number	2020-001202-32
Trial protocol	DE CZ FR NO BE HU PL SE DK IT ES
Global end of trial date	22 February 2024

### Results information

Result version number	v1 (current)
This version publication date	11 April 2025
First version publication date	11 April 2025

### Trial information

#### Trial identification

Sponsor protocol code	TA799-007
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04627025
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	VectivBio AG
Sponsor organisation address	Aeschenvorstadt 36, Basel, Switzerland,
Public contact	Clinical Trial Information Desk, VectivBio AG, ClinicalTrialEnquiries@ironwoodpharma.com
Scientific contact	Clinical Trial Information Desk, VectivBio AG, ClinicalTrialEnquiries@ironwoodpharma.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 February 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	22 February 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency

Protection of trial subjects:

The trial was conducted in compliance with Good Clinical Practice (GCP), the Declaration of Helsinki, and applicable regulatory requirements to ensure the safety, rights, and well-being of all participants. Before enrollment, all subjects provided written informed consent, and the study protocol was approved by Ethics Committees (ECs) and Health Authorities in each participating country.

Subjects were monitored throughout the study for adverse events (AEs), serious adverse events (SAEs), and protocol compliance. An independent Data Monitoring Committee (DMC) periodically reviewed safety data to assess potential risks and recommend necessary actions.

To minimize risks, eligibility criteria were strictly defined to include only subjects for whom the investigational product was deemed appropriate. Measures were in place to protect vulnerable populations, ensuring confidentiality of personal data and adherence to local data protection laws.

Study investigators received comprehensive training on the protocol, safety reporting procedures, and risk mitigation strategies. Any protocol deviations impacting subject safety were documented and reviewed.

Throughout the trial, continuous medical oversight was provided, with subjects able to withdraw at any time without consequences to their medical care. Post-study follow-up ensured that any treatment-related concerns were addressed appropriately.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 December 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 3
Country: Number of subjects enrolled	Israel: 4
Country: Number of subjects enrolled	Japan: 9
Country: Number of subjects enrolled	Korea, Republic of: 5
Country: Number of subjects enrolled	Taiwan: 1
Country: Number of subjects enrolled	United States: 28
Country: Number of subjects enrolled	Norway: 1
Country: Number of subjects enrolled	Poland: 28

Country: Number of subjects enrolled	Spain: 6
Country: Number of subjects enrolled	Sweden: 1
Country: Number of subjects enrolled	United Kingdom: 10
Country: Number of subjects enrolled	Belgium: 6
Country: Number of subjects enrolled	Czechia: 12
Country: Number of subjects enrolled	Denmark: 3
Country: Number of subjects enrolled	France: 19
Country: Number of subjects enrolled	Germany: 12
Country: Number of subjects enrolled	Hungary: 9
Country: Number of subjects enrolled	Italy: 6
Worldwide total number of subjects	163
EEA total number of subjects	103

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	124
From 65 to 84 years	39
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study started (first patient screened) on 03 December 2020 and was completed on 22 February 2024 (last patient out).

The study was conducted in the EEA (Belgium, Czech Republic, Denmark, France, Germany, Hungary, Italy, Norway, Poland, Spain, Sweden), the United Kingdom, the United States, Argentina, Israel, Japan, South Korea, and Taiwan.

### Pre-assignment

Screening details:

216 subjects were screened, and 163 subjects were randomized. The screening period included an optimization phase for parenteral support (PS) adjustment and a stabilization phase. 53 subjects failed screening, mainly due to failed PS optimization criteria (39.6%), consent withdrawal (28.3%), or failed PS stability criteria (17.0%).

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Active arm
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	apraglutide
Investigational medicinal product code	
Other name	TA799
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Apraglutide was administered as a once-weekly (QW) subcutaneous (SC) injection. Two doses was used based on subject`s weight at the most recent study visit (low dose for subjects with a body weight <50 kg or high dose for subjects with a body weight ≥50 kg).

<b>Arm title</b>	Placebo arm
Arm description: -	
Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo was administered as a once-weekly subcutaneous (SC) injection.

<b>Number of subjects in period 1</b>	Active arm	Placebo arm
Started	110	53
Completed	104	51
Not completed	6	2
Consent withdrawn by subject	1	-
Adverse event, non-fatal	4	1
Death	1	-
Protocol deviation	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	Active arm
-----------------------	------------

Reporting group description: -
--------------------------------

Reporting group title	Placebo arm
-----------------------	-------------

Reporting group description: -
--------------------------------

Reporting group values	Active arm	Placebo arm	Total
Number of subjects	110	53	163
Age categorical			
Units: Subjects			
Adults (18-64 years)	87	37	124
From 65-84 years	23	16	39
85 years and over	0	0	0
Gender categorical			
Units: Subjects			
Female	66	26	92
Male	44	27	71

## End points

### End points reporting groups

Reporting group title	Active arm
Reporting group description: -	
Reporting group title	Placebo arm
Reporting group description: -	

### Primary: Primary Endpoint: Relative change from baseline in actual weekly parenteral support (PS) volume at Week 24 (overall population)

End point title	Primary Endpoint: Relative change from baseline in actual weekly parenteral support (PS) volume at Week 24 (overall population)
End point description:	
End point type	Primary
End point timeframe:	
Baseline to Week 24	

End point values	Active arm	Placebo arm		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	110	53		
Units: % change from baseline				
least squares mean (confidence interval 95%)	-25.5 (-31.6 to -19.4)	-12.5 (-17.6 to -7.5)		

### Statistical analyses

Statistical analysis title	Primary endpoint statistical analysis
Comparison groups	Active arm v Placebo arm
Number of subjects included in analysis	163
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001
Method	mixed effect model repeated measures
Parameter estimate	Median difference (final values)
Point estimate	-13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.9
upper limit	-5
Variability estimate	Standard error of the mean
Dispersion value	4.1

---

**Secondary: First Key Secondary Endpoint: PS Reduction of At Least 1 Day per Week from Baseline at Week 24 in the Overall Population**

---

End point title	First Key Secondary Endpoint: PS Reduction of At Least 1 Day per Week from Baseline at Week 24 in the Overall Population
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:  
from baseline to week 24

---

End point values	Active arm	Placebo arm		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	110	53		
Units: Proportion (%)				
number (confidence interval 95%)	43.0 (33.6 to 52.5)	27.5 (15.2 to 39.7)		

**Statistical analyses**

<b>Statistical analysis title</b>	Analysis for the first key secondary endpoint
Comparison groups	Placebo arm v Active arm
Number of subjects included in analysis	163
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.04
Method	Mantel-Haenszel
Parameter estimate	Risk difference (RD)
Point estimate	15.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.7
upper limit	30.5

---

**Secondary: Second Key Secondary Endpoint: Relative Change from Baseline in Actual Weekly PS Volume at Week 24 in the Stoma Subpopulation**

---

End point title	Second Key Secondary Endpoint: Relative Change from Baseline in Actual Weekly PS Volume at Week 24 in the Stoma Subpopulation
-----------------	---

End point description:



End point type	Secondary
End point timeframe: from baseline to week 24	

End point values	Active arm	Placebo arm		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	54 <sup>[1]</sup>	26 <sup>[2]</sup>		
Units: % change from baseline				
least squares mean (confidence interval 95%)	-25.6 (-34.0 to -17.2)	-7.8 (-14.0 to 1.6)		

Notes:

[1] - Stoma subpopulation

[2] - Stoma subpopulation

### Statistical analyses

Statistical analysis title	Analysis for the second key secondary endpoint
Comparison groups	Active arm v Placebo arm
Number of subjects included in analysis	80
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	mixed effect model repeated measures
Parameter estimate	Median difference (final values)
Point estimate	-17.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-28.4
upper limit	-7.3
Variability estimate	Standard error of the mean
Dispersion value	5.4

### Secondary: Third Key Secondary Endpoint: PS Reduction of At Least 1 Day per Week from Baseline at Week 48 in the CIC Subpopulation

End point title	Third Key Secondary Endpoint: PS Reduction of At Least 1 Day per Week from Baseline at Week 48 in the CIC Subpopulation
-----------------	---

End point description:

End point type	Secondary
End point timeframe: from baseline to week 48	

End point values	Active arm	Placebo arm		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	56 <sup>[3]</sup>	27 <sup>[4]</sup>		
Units: % of subjects				
number (confidence interval 95%)	51.8 (38.0 to 65.3)	44.4 (25.5 to 64.7)		

Notes:

[3] - CIC subpopulation

[4] - CIC subpopulation

## Statistical analyses

Statistical analysis title	Analysis for the third key secondary endpoint
Comparison groups	Active arm v Placebo arm
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.348 <sup>[5]</sup>
Method	Fisher exact
Parameter estimate	Risk difference (RD)
Point estimate	7.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-16.4
upper limit	29.8

Notes:

[5] - A numerically higher proportion of subjects in the apraglutide group compared with the placebo group (29 subjects out of 56, 51.8% vs 12 subjects out of 27, 44.4%) in the CIC subpopulation had a PS reduction of at least 1 day per week at Week 48.

## Secondary: Fourth Key Secondary Endpoint: Enteral Autonomy at Week 48 in the CIC Subpopulation

End point title	Fourth Key Secondary Endpoint: Enteral Autonomy at Week 48 in the CIC Subpopulation
End point description:	
End point type	Secondary
End point timeframe:	
from baseline to week 48	

End point values	Active arm	Placebo arm		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	56 <sup>[6]</sup>	27 <sup>[7]</sup>		
Units: % of subjects				
number (confidence interval 95%)	12.5 (5.2 to 24.1)	7.4 (0.9 to 24.3)		

Notes:

[6] - CIC subpopulation

[7] - CIC subpopulation

### Statistical analyses

<b>Statistical analysis title</b>	Analysis for the fourth key secondary endpoint
Comparison groups	Active arm v Placebo arm
Number of subjects included in analysis	83
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.387 <sup>[8]</sup>
Method	Fisher exact
Parameter estimate	Risk difference (RD)
Point estimate	5.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.9
upper limit	18.5

Notes:

[8] - A higher proportion of subjects in the apraglutide group compared with the placebo group (7 subjects [12.5%] vs 2 subjects [7.4%]) in the CIC subpopulation reached enteral autonomy at Week 48.

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Throughout the trial from the time of obtaining informed consent until the last protocol-specific procedure, whether it is the EOT Visit or Early Termination Visit, or a safety follow-up period.

Adverse event reporting additional description:

None of SAEs were assessed as related to apraglutide.

The frequency threshold is applied for the number of affected subjects.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	Active arm
-----------------------	------------

Reporting group description: -

Reporting group title	Placebo arm
-----------------------	-------------

Reporting group description: -

Serious adverse events	Active arm	Placebo arm	
Total subjects affected by serious adverse events			
subjects affected / exposed	39 / 110 (35.45%)	17 / 53 (32.08%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events	1	0	
Vascular disorders			
Jugular vein thrombosis			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral artery thrombosis			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Adverse drug reaction			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related thrombosis			

subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperthermia			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden death			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vessel puncture site inflammation			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemothorax			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrothorax			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			

Hepatic enzyme increased subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Gastrointestinal stoma complication subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stoma site haemorrhage subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stoma site hypergranulation subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation subjects affected / exposed	2 / 110 (1.82%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial thrombosis subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Cardiogenic shock			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 110 (0.91%)	2 / 53 (3.77%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood loss anaemia			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Iron deficiency anaemia			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Glaucoma			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			

subjects affected / exposed	1 / 110 (0.91%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Colitis ischaemic			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterocolonic fistula			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Bile duct stone			



subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholangitis			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocholecystitis			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Purpura			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Osteonecrosis			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pathological fracture			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Vascular device infection			
subjects affected / exposed	14 / 110 (12.73%)	5 / 53 (9.43%)	
occurrences causally related to treatment / all	0 / 16	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	

Gastroenteritis norovirus			
subjects affected / exposed	2 / 110 (1.82%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	1 / 110 (0.91%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related sepsis			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulitis			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis Escherichia coli			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Influenza			

subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella bacteraemia			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurological infection			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic pulmonary embolism			
subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal sepsis			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			

subjects affected / exposed	0 / 110 (0.00%)	1 / 53 (1.89%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular access site infection			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malnutrition			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolic acidosis			
subjects affected / exposed	1 / 110 (0.91%)	0 / 53 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Active arm	Placebo arm	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	98 / 110 (89.09%)	47 / 53 (88.68%)	
Investigations			
Weight decreased			
subjects affected / exposed	7 / 110 (6.36%)	3 / 53 (5.66%)	
occurrences (all)	9	3	
Lipase increased			

subjects affected / exposed occurrences (all)	2 / 110 (1.82%) 2	3 / 53 (5.66%) 3	
C-reactive protein increased subjects affected / exposed occurrences (all)	1 / 110 (0.91%) 1	3 / 53 (5.66%) 4	
Vascular disorders Hypotension subjects affected / exposed occurrences (all)	6 / 110 (5.45%) 7	1 / 53 (1.89%) 1	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	14 / 110 (12.73%) 25	6 / 53 (11.32%) 19	
Dizziness subjects affected / exposed occurrences (all)	6 / 110 (5.45%) 7	1 / 53 (1.89%) 1	
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	11 / 110 (10.00%) 11	3 / 53 (5.66%) 3	
Pyrexia subjects affected / exposed occurrences (all)	7 / 110 (6.36%) 9	3 / 53 (5.66%) 4	
Injection site erythema subjects affected / exposed occurrences (all)	6 / 110 (5.45%) 7	2 / 53 (3.77%) 2	
Complication associated with device subjects affected / exposed occurrences (all)	3 / 110 (2.73%) 3	4 / 53 (7.55%) 5	
Oedema peripheral subjects affected / exposed occurrences (all)	4 / 110 (3.64%) 9	3 / 53 (5.66%) 5	
Thirst subjects affected / exposed occurrences (all)	1 / 110 (0.91%) 1	3 / 53 (5.66%) 5	
Gastrointestinal disorders			

Nausea			
subjects affected / exposed	15 / 110 (13.64%)	6 / 53 (11.32%)	
occurrences (all)	16	8	
Abdominal pain			
subjects affected / exposed	11 / 110 (10.00%)	4 / 53 (7.55%)	
occurrences (all)	18	4	
Diarrhoea			
subjects affected / exposed	11 / 110 (10.00%)	5 / 53 (9.43%)	
occurrences (all)	17	7	
Abdominal distension			
subjects affected / exposed	9 / 110 (8.18%)	4 / 53 (7.55%)	
occurrences (all)	12	4	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	2 / 110 (1.82%)	3 / 53 (5.66%)	
occurrences (all)	2	3	
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	7 / 110 (6.36%)	1 / 53 (1.89%)	
occurrences (all)	7	2	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	8 / 110 (7.27%)	5 / 53 (9.43%)	
occurrences (all)	11	8	
Muscle spasms			
subjects affected / exposed	7 / 110 (6.36%)	0 / 53 (0.00%)	
occurrences (all)	9	0	
Back pain			
subjects affected / exposed	5 / 110 (4.55%)	5 / 53 (9.43%)	
occurrences (all)	6	5	
Pain in extremity			
subjects affected / exposed	3 / 110 (2.73%)	4 / 53 (7.55%)	
occurrences (all)	3	4	
Infections and infestations			
Nasopharyngitis			

subjects affected / exposed occurrences (all)	10 / 110 (9.09%) 15	2 / 53 (3.77%) 2	
COVID-19 subjects affected / exposed occurrences (all)	6 / 110 (5.45%) 8	9 / 53 (16.98%) 9	
Urinary tract infection subjects affected / exposed occurrences (all)	6 / 110 (5.45%) 6	2 / 53 (3.77%) 2	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	6 / 110 (5.45%) 6	1 / 53 (1.89%) 1	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	6 / 110 (5.45%) 8	3 / 53 (5.66%) 3	
Dehydration subjects affected / exposed occurrences (all)	5 / 110 (4.55%) 7	3 / 53 (5.66%) 3	
Hypomagnesaemia subjects affected / exposed occurrences (all)	6 / 110 (5.45%) 8	0 / 53 (0.00%) 0	
Hyperkalaemia subjects affected / exposed occurrences (all)	1 / 110 (0.91%) 1	4 / 53 (7.55%) 5	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 May 2021	Protocol Version 4 The amendment updated patient-reported outcome (PRO) assessments (PGIC, PGIS, PGI-TS, PGI-PSI) to ensure consistency across study sites. Inclusion criteria were clarified, particularly regarding surgical restrictions and the definition of chronic intestinal constipation (CIC). Exclusion criteria were revised to allow cholecystectomy within six months prior to screening. Additionally, stable dose definitions for parenteral support (PS) and other medications were refined. Reason: Improve clarity and consistency of study eligibility criteria and outcome assessments.
13 December 2021	Protocol Version 5: This amendment further modified PRO assessments and adjusted eligibility criteria by refining screening requirements for conditions such as cholecystitis, catheter infections, and prior use of GLP-2/GLP-1 analogues. A new exclusion criterion was added for subjects with familial adenomatous polyposis to enhance patient safety. Reason: Align eligibility criteria with evolving regulatory expectations and ensure scientific rigor.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported